SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The community is rallying behind the multichain meme project crow with knife, highlighting its deflationary burn mechanism and organic growth as primary drivers of their bullish sentiment. Discussions are dominated by high-energy engagement and a strong conviction that the token serves as a unique asset within the current meme coin landscape.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in popularity as the community rallies around its status as a long-standing parody of Bitcoin, with users debating whether its satirical roots give it staying power as a legitimate asset. Supporters are actively pointing to its unique lore, growing holder count, and high-profile endorsements as catalysts, while others remain skeptical, fueling a polarized discussion about its long-term potential in the meme coin space.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as institutional investors debate whether the sector's aggressive AI-driven rally is facing a distribution phase or a continuation setup. The community is heavily focused on the disconnect between soaring AI infrastructure capex and mounting concerns over data center cancellations, power grid constraints, and valuation premiums.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure and negative sentiment as investors express frustration over prolonged stagnant price action and its consistent underperformance compared to other assets. The community is actively debating the project's long-term utility versus its speculative nature, while many are focused on the impact of upcoming legislative developments and potential accumulation opportunities during this period of high volatility.

Maulcoin

Maulcoin is trending as its community aggressively rallies behind the project's organic growth and 'join the dark side' branding, with members actively pushing for social engagement and new listings to drive the next wave of price appreciation. Investors are heavily focused on holding through dips and hitting specific market cap milestones that trigger community-wide airdrops, highlighting a strong collective sentiment centered on long-term accumulation rather than short-term gains.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care (FMS) is trending as the community debates the competitive landscape for infection prevention in dialysis, specifically regarding the adoption and impact of antimicrobial catheter lock solutions like Defencath. Investors are actively tracking potential partnerships and the strategic implications of these technologies on facility-level infection metrics as operators strive to improve patient safety outcomes.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is currently trending as investors weigh the potential long-term impact of GLP-1 weight-loss drugs on the demand for dialysis services, leading to significant market volatility. While some community members view the sharp price drop as a major overreaction based on distant speculation, others are actively debating the sustainability of the company's business model and debt load in light of emerging medical treatments.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as a leading proxy for SpaceX, driven by investor optimism surrounding a potential high-valuation IPO and the company's significant equity stake acquired through recent spectrum deals. Market participants are actively debating the company's valuation metrics and the potential for a short squeeze, positioning the stock as a high-beta setup tied to the upcoming space sector catalysts.

Team, Inc. engages in the provision of fully-integrated, customized solutions for specialty industrial services. It operates through the Inspection and Heat Treating (IHT) and Mechanical Services (MS) segments. The IHT segment offers non-destructive testing services primarily for the process, pipeline and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. The MS segment refers to solutions designed to serve clients’ needs during both the operational (onstream) and off-line states of assets. Its onstream services include a range of standard to custom-engineered leak repair and composite solutions, emissions control and compliance, hot tapping and line stopping, and on-line valve insertion solutions. The company was founded in 1973 and is headquartered in Sugar Land, TX.

Team, Inc.

Team, Inc. is currently attracting attention due to a combination of significant insider buying and positive sentiment surrounding its strategic turnaround, with investors closely watching the company's efforts to reduce debt and improve operational margins. The stock is also benefiting from broader market interest in industrial and energy infrastructure services, which are perceived as beneficiaries of current geopolitical and macro-economic trends.

Zoracles

Zoracles is facing intense community discussion as investors debate whether the current price decline is a shakeout fueled by broader crypto market volatility or a sign of deeper structural issues. While some market participants are aggressively dollar-cost averaging in anticipation of future catalysts like the Clarity Act and ecosystem expansion, others are frustrated by persistent downward pressure and are questioning the long-term viability of the project.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15...

Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold

Wall Street Zen lowered KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVistas Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each...

KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High - Should You Buy?

KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 52-Week High - Time to Buy...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. One...

Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV

Hennion & Walsh Asset Management Inc. raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 93.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 341,8...

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership...

HC Wainwright Has Negative Forecast for KALV FY2028 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at HC Wainwright cut their FY2028 earnings estimates for shares of KalVista Pharmaceuticals in a research report...

KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells $2,960,232.75 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the firm's stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total value of $2,960,232.75. Following the...

KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the business's stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $18.28, for a total value of $730,944.08...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Current Price	$19.39
Prev Close	$19.95
Open	$19.92
Dividend Yield	0.00%
50-Day Moving Average	$16.82
Beta	0.85
Avg. Volume	1.22M
PE Ratio	-4.85

52-Week High	$21.31
52-Week Low	$9.83
Market Capitalization	$993.2M
EPS (Annual)	-$3.23
Price to Book	-364.06
Revenue Per Employee	$267,698.18

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALV News

KALVKalVista Pharmaceuticals Inc